Momentum Builds for Local Drug Production

Why It Matters

Building a self‑sufficient pharma base will improve health security and curb rising drug costs, while creating a new industrial growth engine for Africa.

Key Takeaways

• Africa imports >70% medicines, 99% vaccines.
• Only ~375 local manufacturers versus 5,000 in China.
• API production stays offshore, limiting value capture.
• Utilisation rates 30‑60% raise unit costs.
• AU aims 60% local vaccine production by 2040.

Pulse Analysis

The continent’s heavy reliance on imported medicines has long inflated prices and left patients exposed to global supply chain disruptions. Shipping fees, tariffs, and volatile exchange rates add layers of cost to already scarce generic drugs, while frequent stock‑outs undermine public health outcomes. By contrast, regions with robust domestic manufacturing can stabilize prices and ensure timely access, a competitive advantage that African governments are eager to replicate as out‑of‑pocket spending strains household budgets.

Africa’s pharmaceutical ecosystem remains concentrated at the low‑value end of the supply chain. Most firms import active pharmaceutical ingredients from Asia and focus on formulation and packaging, a model that captures little of the sector’s total value. Capacity utilisation hovers between 30% and 60%, far below the 70%+ benchmarks of developed economies, inflating unit costs and limiting export potential. Scaling up facilities, investing in API production, and improving workforce skills are essential steps to shift the value chain upstream and achieve economies of scale.

Policy responses are coalescing around demand aggregation and regulatory harmonisation. The Platform for Harmonised African Health Products Manufacturing, the African Medicines Agency, and the African Pooled Procurement Mechanism aim to align incentives, streamline approvals, and guarantee long‑term purchase commitments. These tools reduce investment risk and create a predictable market for local manufacturers. If the continent can secure the high‑volume contracts needed to run plants at optimal capacity, it could not only meet its own health needs but also emerge as a cost‑competitive supplier for global markets, reshaping Africa’s economic landscape.